A new study reveals that patients suffering from moderate-to-severe dry eye disease (DED) saw clinical improvement in tear production and dry eye symptoms after being treated with cyclosporine A gel.
The study results were published in Drug Design, Development and
Therapy Journal. The study was a multicenter, randomized, double-masked, vehicle-controlled phase III study that took place between November 2020 and April 2021 and involved over 600 participants.
Participants were assigned to a group to receive either the cyclosporine A drops or vehicle eye drops once a night. The proportion of patients who improved by at least one point in the inferior corneal staining score (ICSS) at day 84 was the primary endpoint of the study.
Researchers found that the proportion of patients who had at least 1-point improvement in ICSS from baseline to day 84 in the cyclosporine A group was significantly higher than in the vehicle group. The cyclosporine a group also had better tear production compared to the vehicle group and the therapy was well-tolerated with only minimal eye discomfort reported.
The study demonstrated that cyclosporine A gel drops are an effective and safe treatment for those suffering from moderate-to-severe dry eye disease and also offers the convenience of being a once-a-day therapy.
